Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Found 1 result for Bookshelf (from PubChem Substance) for id: 393442673
Filters applied. Clear all
Review

Voxelotor

No authors listed
In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006.
.
Free Books & Documents
Review

Voxelotor

No authors listed.
Free Books & Documents

Excerpt

Voxelotor is an orally administered drug that binds to hemoglobin S, inhibiting polymerization. No information is available on the appearance of voxelotor in milk or on the safety of the drug in breastfed infants, but its low molecular weight of 337 Da indicates that it probably passes into milk. Because of the potential for serious adverse reactions in the infant, breastfeeding is currently not recommended during treatment and for at least 2 weeks after the last dose.

PubMed Disclaimer

Similar articles

  • Leniolisib.
    [No authors listed] [No authors listed] 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 37094051 Free Books & Documents. Review.
  • Sotorasib.
    [No authors listed] [No authors listed] 2021 Sep 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2021 Sep 20. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 34554671 Free Books & Documents. Review.
  • Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J, Saraf SL, Gordeuk VR. Han J, et al. Pharmacotherapy. 2020 Jun;40(6):525-534. doi: 10.1002/phar.2405. Epub 2020 May 19. Pharmacotherapy. 2020. PMID: 32343424
  • A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC, Diuguid DL, Telfer P, Tsitsikas DA, Elghandour A, Gordeuk VR, Kanter J, Abboud MR, Lehrer-Graiwer J, Tonda M, Intondi A, Tong B, Howard J; HOPE Trial Investigators. Vichinsky E, et al. N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14. N Engl J Med. 2019. PMID: 31199090 Clinical Trial.
  • A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J, Hemmaway CJ, Telfer P, Layton DM, Porter J, Awogbade M, Mant T, Gretler DD, Dufu K, Hutchaleelaha A, Patel M, Siu V, Dixon S, Landsman N, Tonda M, Lehrer-Graiwer J. Howard J, et al. Blood. 2019 Apr 25;133(17):1865-1875. doi: 10.1182/blood-2018-08-868893. Epub 2019 Jan 17. Blood. 2019. PMID: 30655275 Free PMC article. Clinical Trial.
See all similar articles

LinkOut - more resources

-